PAncreatic Disease Cohort of TOuLouse

Recruiting

• Conditions: Pancreatic Diseases

• Registration Number: NCT05824403
• Lead Sponsor: University Hospital, Toulouse

Brief Summary

This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.

Detailed Description

This collection focuses on pathology of the pancreas requiring specific investigations or management for diagnosis or treatment. Pancreatic pathologies can be classified as malignant, potentially malignant or benign tumors. These can be solid or cystic. There is an inflammatory attack on the pancreas, generating acute pancreatitis in the acute period, if the inflammatory manifestations persist, chronic pancreatitis will develop. Some lesions may be at risk of malignancy during their evolution, it is therefore necessary to improve the performance of monitoring and diagnostic tools in order to adapt the management of patients.

Study Timeline

• Study First Submitted: 2023-03-27
• Study First Submitted QC: 2023-04-19
• Study First Posted: 2023-04-21
• Status Verified: 2023-11
• Study Start: 2023-11-28
• Last Update Submitted: 2023-11-28
• Last Update Posted: 2023-12-04
• Primary Completion: 2027-12
• Study Completion: 2027-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Patients with inflammatory or cystic exocrine pancreatic pathology
• Patient able to read and understand the information leaflet
• Patients who have agreed to participate in the study and have signed the free and informed consent
• Patients affiliated to a social security system (including AME)

Exclusion Criteria

• Patient with pancreatic cancer pathology
• Patients with active cancer, whatever the origin
• Pregnant or breastfeeding patients
• Patients under legal protection, guardianship or trusteeship

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diagnostic tools	3 years after the first inclusion	To develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies

Secondary Outcome Measures

Name	Time	Method
Microbiota	3 years after the first inclusion	Study of the microbiota of pancreatic diseases
New targets	3 years after the first inclusion	To identify new screening targets
Improvement of management	3 years after the first inclusion	To improve the management of cystic lesions or Chronic pancreatitis on the decision of therapeutic management
Clinical data access	3 years after the first inclusion	To make available to the scientific community quality material with associated clinical data also of quality

Trial Locations

Locations (1)

Rangueil hospital; 🇫🇷 Toulouse, France